Breakthrough
Nicotinamide Riboside + Pterostilbene (Basis): The Combination NAD Product Trial Legacy
"Basis" is the trade name of the first major commercial NAD precursor combination — 250 mg of nicotinamide riboside (NR) plus 50 mg of pterostilbene per day — launched by Elysium Health in 2014 under unusual academic-industry circumstances